Brief: Biocon Enters Global Settlement And License Agreement With Genentech For Pebrilzo
14/10/2026 04:27
BRIEF-Biocon Enters Global Settlement And License Agreement With Genentech For Pebrilzo Oct 14 (Reuters) - Biocon Limited BION.NS:
BIOCON - ENTERS GLOBAL SETTLEMENT AND LICENSE AGREEMENT WITH GENENTECH FOR PEBRILZO
BIOCON - TO LAUNCH PEBRILZO IN Q1 CY2027 IN EU AND UK, Q3 CY2028 IN U.S., CY2026-2028 IN ROW
BIOCON - CO AND GENENTECH RESOLVE ALL PENDING PATENT DISPUTES IN U.S., CANADA, AND OTHER JURISDICTIONS
Source text: ID:nNSE1DJR53
Further company coverage: BION.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biocon
See all newsBiocon settles Roche's US patent lawsuit over proposed breast-cancer drug copy
Brief: Biocon Enters Global Settlement And License Agreement With Genentech For Pebrilzo
Existential threats join bubble fears as AI mood sobers at Singapore forums
Brief: Activ Pine LLP Sells 16.6 Million Of Biocon Shares Via Block Deals, As Per BSE Data
Brief: Biocon Secures 10-Year Supply Contract For Pertuzumab In Brazil